Streetbeat News

Revenues

AMRX

Amneal reaffirmed its 2024 revenue guidance of $2.55B-$2.65B, aligning with the consensus estimate of $2.60B. The company also provided an adjusted EBITDA forecast of $0.53B-$0.63B, compared to previous guidance of $0.58B.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 10:13 am

PRLB

Protolabs expects Q2 2024 revenue to be between $122M-$130M, below the consensus of $128.256M. Adjusted EPS is forecasted to be $0.30-$0.38, under the consensus of $0.39.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 10:09 am

MGA

Magna International has updated its 2024 outlook, now expecting lower sales and adjusted net income than previously forecasted. Sales are projected to be between $42.6B and $44.2B, down from the prior estimate of $43.8B-$45.4B, against analysts' expectations of $44.443B. Adjusted net income is anticipated to be between $1.5B and $1.7B, revised from the earlier range of $1.6B-$1.8B. The company's adjusted EBIT margin and equity income projections remain unchanged, while capital spending is slightly reduced.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 9:18 am

CVNA

DASH

QCOM

U.S. stocks rose with the Dow Jones gaining over 300 points as investor sentiment improved, despite the CNN Money Fear and Greed index indicating a continued state of 'Fear'. The Federal Reserve held interest rates steady, while economic data showed a slight narrowing of the trade deficit and unchanged jobless claims. QUALCOMM, DoorDash, and Carvana saw significant stock movements after their earnings reports. The S&P 500 and Nasdaq also posted gains, with most sectors up except materials and health care. Upcoming earnings include American Axle, Hershey, and Fluor.

Portfolio Pulse from Avi Kapoor

May 03, 2024 | 7:18 am

ANPCY

AZN

ANGLE has signed a supplier agreement with AstraZeneca to develop a Parsortix-based androgen receptor (AR) detection assay for prostate cancer studies, valued at £550,000. The development will occur in ANGLE's UK labs, aiming for completion in Q1 2025. Success could highlight Parsortix's role in evaluating prostate cancer treatments and promise ongoing business for ANGLE in supporting clinical studies.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 7:06 am

GGB

Gerdau reported a 14.11% decrease in Q1 sales year-over-year, from R$18.872B to R$16.210B, and an adjusted net income drop from R$2.388B to R$1.245B.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 6:31 am

EWA

Australia's Home Loans for the month showed a significant increase of 2.8%, surpassing the estimated 1.0% and the previous month's 1.6%.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 4:06 am

FET

Forum Energy Technologies reaffirms its FY24 adjusted EBITDA guidance of $100M-$120M and free cash flow of $40M-$60M. The company expects Q2 adjusted EBITDA between $24M-$28M, with stable U.S. and international market activity but lower Canadian demand due to seasonal factors.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:49 pm

OPEN

Opendoor Technologies projects its Q2 revenue to be between $1.4B and $1.5B, which aligns closely with the estimated $1.48B. The company also forecasts a Contribution Profit of $75M to $85M and an Adjusted EBITDA ranging from a loss of $35M to $25M for the same period.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:17 pm

RMAX

RE/MAX Holdings projects Q2 revenue to be between $75M-$80M, below the $78.76M estimate, and FY24 revenue to be between $300M-$320M, aligning with the $310.41M estimate. The outlook assumes stable currency rates, no acquisitions, or divestitures, with a slight negative to positive change in agent count.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:16 pm